Maarten Boers1, John R Kirwan2, George Wells3, Dorcas Beaton4, Laure Gossec5, Maria-Antonietta d'Agostino6, Philip G Conaghan7, Clifton O Bingham8, Peter Brooks9, Robert Landewé10, Lyn March11, Lee S Simon12, Jasvinder A Singh13, Vibeke Strand14, Peter Tugwell15. 1. Department of Epidemiology and Biostatistics, VU University Medical Center, PK 6Z 165, PO Box 7057, 1007 MB Amsterdam, The Netherlands. Electronic address: eb@vumc.nl. 2. University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom. 3. Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada. 4. Department of Occupational Science and Occupational Therapy, University of Toronto, Toronto, Ontario, Canada. 5. Department of Rheumatology, Université Pierre et Marie Curie (UPMC), Paris 6, GRC-UMPC 08 (EEMOIS), and Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France. 6. Department of Rheumatology, Université Versailles-Saint Quentin en Yvelines, Ambroise Pare Hospital, Boulogne-Billancourt, France. 7. NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom. 8. Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21224, USA. 9. School of Population and Global Health, University of Melbourne, Melbourne, Australia. 10. Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 11. Institute of Bone and Joint Research, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Department of Rheumatology, Royal North Shore Hospital, St. Leonards, New South Wales, Australia. 12. SDG LLC, Cambridge, MA 02138, USA. 13. Division of Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; Veterans Affairs Medical Center, Birmingham, AL 35294, USA. 14. Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA 94028, USA. 15. Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Abstract
BACKGROUND: Lack of standardization of outcome measures limits the usefulness of clinical trial evidence to inform health care decisions. This can be addressed by agreeing on a minimum core set of outcome measures per health condition, containing measures relevant to patients and decision makers. Since 1992, the Outcome Measures in Rheumatology (OMERACT) consensus initiative has successfully developed core sets for many rheumatologic conditions, actively involving patients since 2002. Its expanding scope required an explicit formulation of its underlying conceptual framework and process. METHODS: Literature searches and iterative consensus process (surveys and group meetings) of stakeholders including patients, health professionals, and methodologists within and outside rheumatology. RESULTS: To comprehensively sample patient-centered and intervention-specific outcomes, a framework emerged that comprises three core "Areas," namely Death, Life Impact, and Pathophysiological Manifestations; and one strongly recommended Resource Use. Through literature review and consensus process, core set development for any specific health condition starts by identifying at least one core "Domain" within each of the Areas to formulate the "Core Domain Set." Next, at least one applicable measurement instrument for each core Domain is identified to formulate a "Core Outcome Measurement Set." Each instrument must prove to be truthful (valid), discriminative, and feasible. In 2012, 96% of the voting participants (n=125) at the OMERACT 11 consensus conference endorsed this model and process. CONCLUSION: The OMERACT Filter 2.0 explicitly describes a comprehensive conceptual framework and a recommended process to develop core outcome measurement sets for rheumatology likely to be useful as a template in other areas of health care.
BACKGROUND: Lack of standardization of outcome measures limits the usefulness of clinical trial evidence to inform health care decisions. This can be addressed by agreeing on a minimum core set of outcome measures per health condition, containing measures relevant to patients and decision makers. Since 1992, the Outcome Measures in Rheumatology (OMERACT) consensus initiative has successfully developed core sets for many rheumatologic conditions, actively involving patients since 2002. Its expanding scope required an explicit formulation of its underlying conceptual framework and process. METHODS: Literature searches and iterative consensus process (surveys and group meetings) of stakeholders including patients, health professionals, and methodologists within and outside rheumatology. RESULTS: To comprehensively sample patient-centered and intervention-specific outcomes, a framework emerged that comprises three core "Areas," namely Death, Life Impact, and Pathophysiological Manifestations; and one strongly recommended Resource Use. Through literature review and consensus process, core set development for any specific health condition starts by identifying at least one core "Domain" within each of the Areas to formulate the "Core Domain Set." Next, at least one applicable measurement instrument for each core Domain is identified to formulate a "Core Outcome Measurement Set." Each instrument must prove to be truthful (valid), discriminative, and feasible. In 2012, 96% of the voting participants (n=125) at the OMERACT 11 consensus conference endorsed this model and process. CONCLUSION: The OMERACT Filter 2.0 explicitly describes a comprehensive conceptual framework and a recommended process to develop core outcome measurement sets for rheumatology likely to be useful as a template in other areas of health care.
Authors: Dinesh Khanna; Shikha Mittoo; Rohit Aggarwal; Susanna M Proudman; Nicola Dalbeth; Eric L Matteson; Kevin Brown; Kevin Flaherty; Athol U Wells; James R Seibold; Vibeke Strand Journal: J Rheumatol Date: 2015-03-01 Impact factor: 4.666
Authors: Louise Klokker; Richard Osborne; Eva E Wæhrens; Ole Norgaard; Elisabeth Bandak; Henning Bliddal; Marius Henriksen Journal: Qual Life Res Date: 2015-04-17 Impact factor: 4.147
Authors: Karine Toupin-April; Jennifer Barton; Liana Fraenkel; Linda Li; Viviane Grandpierre; Francis Guillemin; Tamara Rader; Dawn Stacey; France Légaré; Janet Jull; Jennifer Petkovic; Marieke Scholte-Voshaar; Vivian Welch; Anne Lyddiatt; Cathie Hofstetter; Maarten De Wit; Lyn March; Tanya Meade; Robin Christensen; Cécile Gaujoux-Viala; Maria E Suarez-Almazor; Annelies Boonen; Christoph Pohl; Richard Martin; Peter S Tugwell Journal: J Rheumatol Date: 2015-04-15 Impact factor: 4.666
Authors: Joanna C Robson; Gunnar Tomasson; Nataliya Milman; Sue Ashdown; Annelies Boonen; George C Casey; Peter F Cronholm; David Cuthbertson; Jill Dawson; Haner Direskeneli; Ebony Easley; Tanaz A Kermani; John T Farrar; Don Gebhart; Georgia Lanier; Raashid A Luqmani; Alfred Mahr; Carol A McAlear; Jacqueline Peck; Beverley Shea; Judy A Shea; Antoine G Sreih; Peter S Tugwell; Peter A Merkel Journal: J Rheumatol Date: 2017-09-01 Impact factor: 4.666
Authors: Vivian P Bykerk; Elisabeth Lie; Susan J Bartlett; Rieke Alten; Annelies Boonen; Robin Christensen; Daniel E Furst; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; James E May; Pam Montie; Ana-Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia Woodworth; Clifton O Bingham; Ernest H Choy Journal: J Rheumatol Date: 2014-03-01 Impact factor: 4.666
Authors: Jonathan T L Cheah; Rachel J Black; Joanna C Robson; Iris Y Navarro-Millán; Sarah R Young; Pamela Richards; Susan Beard; Lee S Simon; Susan M Goodman; Sarah L Mackie; Catherine L Hill Journal: J Rheumatol Date: 2019-01-15 Impact factor: 4.666